Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs

Leanne M. Johnson-Huang, Cara A. Pensabene, Kejal R. Shah, Katherine C. Pierson, Toyoko Kikuchi, Tim Lentini, Patricia Gilleaudeau, Mary Sullivan-Whalen, Inna Cueto, Artemis Khatcherian, Luke A. Hyder, Mayte Suárez-Fariñas, James G. Krueger, Michelle A. Lowes

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


To understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3 + T cells, neutrophils, CD11c + and CD83 + myeloid dendritic cells (DCs), but no increase in CD1c + resident myeloid DCs. In relapsed lesions, there were many CD11c +CD1c -, inflammatory myeloid DCs identified by TNFSF10/TRAIL, TNF, and iNOS. CD11c + cells in relapsed lesions co-expressed CD14 and CD16 in situ. Efalizumab induced an improvement in many psoriasis genes, and during relapse, the majority of these genes reversed back to a lesional state. Gene Set Enrichment Analysis (GSEA) of the transcriptome of relapsed tissue showed that many of the gene sets known to be present in psoriasis were also highly enriched in relapse. Hence, on ceasing efalizumab, T cells and myeloid cells rapidly enter the skin to cause classic psoriasis. Trial registration: NCT00115076.

Original languageEnglish (US)
Article numbere30308
JournalPloS one
Issue number2
StatePublished - 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General


Dive into the research topics of 'Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs'. Together they form a unique fingerprint.

Cite this